RC
LSTA icon

Rangeley Capital’s Lisata Therapeutics LSTA Stock Holding History

Rangeley Capital’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$376K Buy
+75,000
New +$310K 0.37% 60

Other funds holding LSTA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

Rangeley Capital's LSTA Position: Q1 2026 in Review

Rangeley Capital opened a new position in Lisata Therapeutics (LSTA) in Q1 2026: 75,000 shares worth $376K. The stake represents 0.37% of the portfolio and ranks #60 among its holdings.

34 funds tracked by Wall St. Rank hold LSTA as of Q1 2026.

  • Rangeley Capital held 75,000 shares of Lisata Therapeutics worth $376K as of Q1 2026.
  • Lisata Therapeutics was a new Rangeley Capital position in Q1 2026.
  • Lisata Therapeutics made up 0.37% of Rangeley Capital's portfolio in Q1 2026, its #60 holding.
  • 34 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.